KITE-753

Phase 3Small molecule

KITE-753 is one of 23 small molecule programs targeting Relapsed and/or Refractory B-cell Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed And/or Refractory B-Cell LymphomaRecruiting

B-Cell Acute Lymphoblastic LeukemiaNot yet recruiting

Relapsed or Refractory Large B-Cell LymphomaRecruiting

Relapsed And/or Refractory B-Cell LymphomaPreclinical

Recruiting

B-Cell Acute Lymphoblastic LeukemiaPhase 1

Not yet recruiting

Relapsed or Refractory Large B-Cell LymphomaPhase 3

Recruiting

Competition

Competitive Landscape

27 competitors in B-Cell Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Dacogen

Sun Pharmaceutical Industries, Inc.

Fludara

7 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

9 4

Blincyto

Amgen

Phase 2

4 5

Tisagenlecleucel

Novartis

Phase 2

1 6

KITE-753

Gilead

Phase 3

1 7

CTL019

Novartis

Phase 3

2 8

Erbitux

IImclone

Phase 1

1 9

YK012

EExcyte Biopharma Ltd

Phase 2

1 10

Inaticabtagene Autoleucel

JJuventas Cell Therapy Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

PreclinicalRecruiting

Relapsed And/or Refractory B-Cell Lymphoma

NCT04989803

Q2 2031

Phase 1Not yet recruiting

B-Cell Acute Lymphoblastic Leukemia

NCT07674823

Phase 3Recruiting

Relapsed or Refractory Large B-Cell Lymphoma

NCT07479797

Clinical

Trials by Indication[1]

Long-term Follow-up1 trial

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Enrolling by invitation· Gilead logo

Gilead··NCT05041309·1,000 enrolled

B-cell acute lymphoblastic leukemia1 trial

A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07674823·18 enrolled

Relapsed or Refractory Large B-cell Lymphoma1 trial

A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

Recruiting· Gilead logo

Gilead·Phase 3·NCT07479797·550 enrolled

Relapsed and/or Refractory B-cell Lymphoma1 trial

A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma

Recruiting· Gilead logo

Gilead·Preclinical·NCT04989803·247 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for KITE-753. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KITE-753 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KITE-753. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Gilead

KITE-753

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Q2 2031

Trials by Indication[1]

Long-term Follow-up1 trial

B-cell acute lymphoblastic leukemia1 trial

Relapsed or Refractory Large B-cell Lymphoma1 trial

Relapsed and/or Refractory B-cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News